NCEL

6-K - NewcelX Ltd. (0001783036) (Filer)

ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent Number BR 112018010946-0 covering its innovative cell selection and enrichment technology. The patent protects the manufacturing process of its lead clinical compound, NCEL-101, until November 2036. "The patent grant follows our recently announced successful FDA Type B Pre-IND meeting for NCEL-101, in combination with Eledon’s anti-CD40L monoclonal antibody, tegoprubart, for the treatment of type 1 diabetes, providing a clear regulatory pathwa

6-K - NewcelX Ltd. (0001783036) (Filer)

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials Dr. Ricordi to support advancement of NewcelX's Type 1 Diabetes program and strategic collaboration with Eledon Pharmaceuticals ZURICH, July 08, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biotechnology company developing regenerative cell therapies for type 1 diabetes and other serious diseases, today announced the appointment of Camillo Ricordi, M.D., F.N.A.I., to its Scientific Advisory Board. Dr. Ricordi is internationally recognized as one of the world's foremost authorities in diabetes cure-fo

Issued on behalf of Avaí Bio, Inc.As cell-based medicine moves from the lab toward the clinic across diabetes, transplant, and aging, Avaí Bio and partner Austrianova have banked the genetically modified cells that will manufacture their encapsulated alpha-Klotho productLAS VEGAS, July 8, 2026 /CNW/ -- USA News Group News Commentary - The most valuable real estate in medicine right now is a living cell. Across diabetes, organ transplant, and the fast-emerging field of longevity biology, developers are racing to turn engineered and donor-derived cells into durable, manufacturable therapies, and the companies that reach GMP-grade production first are the ones the market takes seriously. That i

6-K - NewcelX Ltd. (0001783036) (Filer)

ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion of its Type B Pre-IND meeting with the U.S. Food and Drug Administration ("FDA"). The agency provided constructive feedback and alignment on the Company’s proposed development strategy, providing clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an investigational immunomodulatory agent. The meeting results represent a significant milestone t

6-K - NewcelX Ltd. (0001783036) (Filer)

EFFECT - NewcelX Ltd. (0001783036) (Filer)

6-K - NewcelX Ltd. (0001783036) (Filer)

Study published in Stem Cell Reports demonstrates that AstroRx® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS Showcases scalability and broad therapeutic potential of the Company's stem cell therapy platform as it advances a potential cure for type 1 diabetes ZURICH, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx®, a clinical-grade human embryonic stem

F-3/A - NewcelX Ltd. (0001783036) (Filer)

6-K - NewcelX Ltd. (0001783036) (Filer)

6-K - NewcelX Ltd. (0001783036) (Filer)

Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi

EFFECT - NewcelX Ltd. (0001783036) (Filer)

D - NewcelX Ltd. (0001783036) (Filer)

F-3 - NewcelX Ltd. (0001783036) (Filer)

EFFECT - NewcelX Ltd. (0001783036) (Filer)

POS AM - NewcelX Ltd. (0001783036) (Filer)

6-K - NewcelX Ltd. (0001783036) (Filer)

NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan

20-F - NewcelX Ltd. (0001783036) (Filer)

4 - NewcelX Ltd. (0001783036) (Issuer)

4 - NewcelX Ltd. (0001783036) (Issuer)